Search clinical trials for: NNC9204-0530

Total 85 results

Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Obesity | Overweight | Healthy Volunteers

United States
Novo Nordisk A/S

Completed

A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Recruiting

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Healthy Volunteers (Diabetes Mellitus, Type 2)

Denmark, Germany
Novo Nordisk A/S

Completed

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Not yet recruiting

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Diabetes Mellitus, Type 2

Germany
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Diffuse Large B Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Mantle Zone Lymphoma Refractory/Recurrent | Follicle Centre Lymphoma Diffuse

China
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Wellmarker Bio
Covance

Recruiting

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor

Korea, Republic of, Australia
Keros Therapeutics, Inc.

Recruiting

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Cytopenia

Australia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States, New Zealand
Novo Nordisk A/S

Completed

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)

Chronic Hepatitis C Virus (HCV) Infection
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

Solid Tumor

Germany
Novo Nordisk A/S

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Korea, Republic of, India, Australia, Canada, Japan, South Africa
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Renal Impairment

United States, New Zealand
Keros Therapeutics, Inc.
IQVIA Biotech

Recruiting

Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis

Myelofibrosis

Australia
AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
AbbVie

Approved for marketing

Expanded Access to Glecaprevir/ Pibrentasvir

Hepatitis C Virus Infection

Slovenia
HaEmek Medical Center, Israel

Withdrawn

Different Modes of Temperature Measurement in the Emergency Department

Sepsis

Israel
AbbVie

Completed

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) (ENDURANCE-4)

Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Hepatitis C Virus (HCV)

Brazil
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
Double Bond Pharmaceutical AB

Not yet recruiting

A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM (TARGLIO)

Newly Diagnosed Glioblastoma
Andres Duarte-Rojo

Completed

Controlled Attenuation Parameter (CAP) in Liver Allografts

Liver Disease | Early Allograft Dysfunction | Liver Steatosis | Liver Transplant | Primary Non-function

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
Trishula Therapeutics, Inc.
AbbVie

Completed

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Solid Tumor, Adult

United States, Korea, Republic of
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Chronic Hepatitis C | Hepatitis C Virus | HCV | Direct-Acting Antiviral Agent (DAA)-Experienced
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
Nidek Co. LTD.

Completed

Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality

Corneal Endothelial Cell Loss

United States
Echosens

Completed

Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference

Chronic Liver Disease

France
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Not yet recruiting

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Duchenne Muscular Dystrophy

United States
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Hepatitis C Virus (HCV)

United States, Australia, Austria, Canada, France, Germany, Italy, Spain
Nidek Co. LTD.

Completed

Comparative Study of the NIDEK TONOREF III and the Haag-Streit Goldmann Manual Tonometer and Comparison of Pachymetry Values for NIDEK TONOREF III With the NIDEK CEM-530

Intraocular Pressure

United States
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Chronic Hepatitis C | Hepatitis C Virus
Chengdu University of Traditional Chinese Medicine
West China Hospital

Completed

Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome

Chronic Fatigue Syndrome

China
Johnson & Johnson Consumer and Personal Products...

Completed

To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children

Atopic Dermatitis

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
Nidek Co. LTD.

Not yet recruiting

Comparative Study of the NIDEK TONOREF III With Predicate Devices

Intraocular Pressure

United Kingdom
AbbVie

Completed

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Hepatitis C

United States, Australia, Belgium, Canada, Germany, New Zealand, Puerto Rico, United Kingdom
AbbVie

Completed

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (ENDURANCE-3)

Chronic Hepatitis C | Hepatitis C Virus | Genotype 3 Hepatitis C Virus

3

Subscribe